FBIO climber 3 months $3.91 10-day and upper boll
Post# of 122
10-day and upper bollie
Nasdaq CM
Website
Last ten trades
100% x 100% Strong Buy
10-K 3/16/17
Low float
Shares Outstanding 48.88M
Float 27.06M
% Held by Insiders 45.71%
% Held by Institutions 10.10%
Shares Short 3 3.61M
Short Ratio 26.41
Short % of Float 11.20%
Shares Short (prior month) 3.61M
Stock technical analysis
News
and filings
Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its product includes CNDO-109, a lysate that activates donor natural killer cells for the treatment of cancer-related and other conditions. The company, through its subsidiary Caelum Biosciences, Inc., engages in developing CAEL-101 for the treatment of amyloid light chain amyloidosis. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.